^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 overexpression + CD163 underexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, CD163, CD163 Molecule, M130, Scavenger Receptor Cysteine-Rich Type 1 Protein M130, Hemoglobin Scavenger Receptor, CD163 Antigen, SCARI1, MM130, Macrophage-Associated Antigen
    Entrez ID:
    29126; 9332
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Functional status of tumor-associated macrophages impacts clinical outcome of durvalumab in patients with advanced NSCLC as revealed by proteomics mass spectrometry (AACR 2023)
    This analysis further confirms the importance of myeloid cell function within the tumor microenvironment (TME) in determining the outcome to T cell-directed IO therapy and highlights the utility of proteomics mass spectrometry in assessing more broadly and quantitatively the TME complementing findings based on RNAseq and IHC/mIF assays.
    Clinical • Clinical data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD68 (CD68 Molecule)
    |
    PD-L1 overexpression • CD163 expression • CD163 underexpression • PD-L1 overexpression + CD163 underexpression
    |
    Imfinzi (durvalumab)